SRRM2 and Miyoshi myopathy: High expression of SRRM2 in plasma cells of newly diagnosed MM patients is associated with poor prognosis indicators, including elevated levels of serum β2-MG and LDH, higher ISS stage, increased risk of high-risk mSMART 3.0 risk stratification, and increased risk of cytogenetic abnormalities.